Evidence map›Paper›PMID 25436131›Full record

ArticleJournal of gastrointestinal oncology2014

HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report.

Jiaxin Niu, Deborah Gelbspan, David Weitz, Maurie Markman, Walter Quan

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jiaxin Niu1 Department of Medical Oncology, 2 Department of Pathology, 3 Department of Radiology, Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, AZ, USA ; 4 Department of Medical Oncology, Cancer Treatment Centers of America, 5 Drexel University College of Medicine, Philadelphia, PA, USA.
Deborah Gelbspan1 Department of Medical Oncology, 2 Department of Pathology, 3 Department of Radiology, Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, AZ, USA ; 4 Department of Medical Oncology, Cancer Treatment Centers of America, 5 Drexel University College of Medicine, Philadelphia, PA, USA.
David Weitz1 Department of Medical Oncology, 2 Department of Pathology, 3 Department of Radiology, Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, AZ, USA ; 4 Department of Medical Oncology, Cancer Treatment Centers of America, 5 Drexel University College of Medicine, Philadelphia, PA, USA.
Maurie Markman1 Department of Medical Oncology, 2 Department of Pathology, 3 Department of Radiology, Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, AZ, USA ; 4 Department of Medical Oncology, Cancer Treatment Centers of America, 5 Drexel University College of Medicine, Philadelphia, PA, USA.
Walter Quan1 Department of Medical Oncology, 2 Department of Pathology, 3 Department of Radiology, Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, AZ, USA ; 4 Department of Medical Oncology, Cancer Treatment Centers of America, 5 Drexel University College of Medicine, Philadelphia, PA, USA.
Cancer Treatment Centers of America · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We here report a case of a patient diagnosed with human epithelial growth factor receptor 2 (HER2)-amplified esophageal adenocarcinoma. The patient responded well to trastuzumab-based chemotherapy initially, but progressed with liver metastases. Her treatment was then switched to dual HER2 blockade with both trastuzumab and lapatinib in combination with capecitabine. She tolerated therapy and responded remarkably well with radiographic resolution of liver metastases. Unfortunately, she developed multiple brain metastases in the absence of extracranial progression. Discordant negative expression of HER2 and subclonal mutations in brain lesions were discovered, which, at least in part, explained her brain metastases in the presence of capecitabine and lapatinib, as both agents are known to be able to cross the blood brain barrier. The potential mechanism for dual HER2 blockade is discussed in the context of HER2-positive, trastuzumab-resistant, advanced esophageal cancer. The incidence of brain metastasis in advanced gastro-esophageal cancer has been reported to be extremely low, but is expected to increase with more effective systemic therapy. The intratumoral heterogeneity between the metastases, local recurrences and the primary tumor is definitely noteworthy.

Indexed as

brain metastasisEsophageal cancerheterogeneityhuman epithelial growth factor receptor 2 (HER2)resistance

Identifiers

PMID25436131
PMCPMC4226817
OpenAlexW155607845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.